Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BBIO OTCMKTS:EVTCY NASDAQ:NKTR NASDAQ:UTHR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBIOBridgeBio Pharma$66.69-1.0%$69.89$40.19▼$84.94$13.06B0.972.76 million shs1.53 million shsEVTCYEvotec$2.61-3.0%$2.94$14.22▼$26.57$861.88M0.982,407 shs99,878 shsNKTRNektar Therapeutics$59.77-1.9%$73.67$8.27▼$109.00$2.02B1.131.06 million shs280,041 shsUTHRUnited Therapeutics$540.61-2.0%$565.95$272.12▼$609.35$22.95B0.57476,416 shs257,742 shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBIOBridgeBio Pharma+1.13%-0.01%+3.17%-3.96%+68.18%EVTCYEvotec-3.93%-2.18%-0.37%+10.25%-34.87%NKTRNektar Therapeutics+1.08%+7.29%-10.97%-18.60%+597.82%UTHRUnited Therapeutics+0.58%+1.35%-2.74%+4.64%+92.23%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBIOBridgeBio Pharma$66.69-1.0%$69.89$40.19▼$84.94$13.06B0.972.76 million shs1.53 million shsEVTCYEvotec$2.61-3.0%$2.94$14.22▼$26.57$861.88M0.982,407 shs99,878 shsNKTRNektar Therapeutics$59.77-1.9%$73.67$8.27▼$109.00$2.02B1.131.06 million shs280,041 shsUTHRUnited Therapeutics$540.61-2.0%$565.95$272.12▼$609.35$22.95B0.57476,416 shs257,742 shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBIOBridgeBio Pharma+1.13%-0.01%+3.17%-3.96%+68.18%EVTCYEvotec-3.93%-2.18%-0.37%+10.25%-34.87%NKTRNektar Therapeutics+1.08%+7.29%-10.97%-18.60%+597.82%UTHRUnited Therapeutics+0.58%+1.35%-2.74%+4.64%+92.23%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBBIOBridgeBio Pharma 2.84Moderate Buy$91.0535.88% UpsideEVTCYEvotec 0.00N/AN/AN/ANKTRNektar Therapeutics 2.73Moderate Buy$149.63151.26% UpsideUTHRUnited Therapeutics 2.85Moderate Buy$619.4214.71% UpsideCurrent Analyst Ratings BreakdownLatest UTHR, BBIO, NKTR, and EVTCY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2026BBIOBridgeBio Pharma MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$106.00 ➝ $96.006/11/2026UTHRUnited Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy (B)6/3/2026BBIOBridgeBio Pharma Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$104.006/2/2026NKTRNektar Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/28/2026BBIOBridgeBio Pharma Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$94.00 ➝ $98.005/28/2026BBIOBridgeBio Pharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$110.005/26/2026BBIOBridgeBio Pharma Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform5/21/2026UTHRUnited Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/19/2026BBIOBridgeBio Pharma CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$82.005/15/2026BBIOBridgeBio Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)5/11/2026BBIOBridgeBio Pharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$100.00 ➝ $110.00(Data available from 6/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBBIOBridgeBio Pharma$502.08M26.14N/AN/A($10.77) per share-6.22EVTCYEvotec$572.16M1.51$0.02 per share105.53$2.52 per share1.04NKTRNektar Therapeutics$55.63M36.16N/AN/A$4.41 per share13.50UTHRUnited Therapeutics$3.18B7.20$32.49 per share16.62$164.81 per share3.28Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBBIOBridgeBio Pharma-$724.93M-$3.74N/A291.33N/A-124.42%N/A-65.81%8/4/2026 (Estimated)EVTCYEvotec$7.14M$0.416.37N/AN/A20.85%16.02%7.81%N/ANKTRNektar Therapeutics-$164.08M-$8.42N/AN/AN/A-284.18%-85.40%-39.99%8/6/2026 (Estimated)UTHRUnited Therapeutics$1.33B$27.0919.9317.371.7940.62%19.24%17.25%7/29/2026 (Estimated)Latest UTHR, BBIO, NKTR, and EVTCY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026BBIOBridgeBio Pharma-$0.70-$0.84-$0.14-$0.84$178.07 million$194.52 million5/7/2026Q1 2026NKTRNektar Therapeutics-$1.5824-$1.82-$0.2377-$1.82$10.69 million$10.86 million5/6/2026Q1 2026UTHRUnited Therapeutics$7.00$5.82-$1.18$5.82$797.40 million$781.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBBIOBridgeBio PharmaN/AN/AN/AN/AN/AEVTCYEvotecN/AN/AN/AN/AN/ANKTRNektar TherapeuticsN/AN/AN/AN/AN/AUTHRUnited TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBBIOBridgeBio PharmaN/A1.521.48EVTCYEvotec0.532.572.50NKTRNektar TherapeuticsN/A10.2110.21UTHRUnited TherapeuticsN/A4.794.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBBIOBridgeBio Pharma99.85%EVTCYEvotecN/ANKTRNektar Therapeutics75.88%UTHRUnited Therapeutics94.08%Insider OwnershipCompanyInsider OwnershipBBIOBridgeBio Pharma14.23%EVTCYEvotecN/ANKTRNektar Therapeutics2.50%UTHRUnited Therapeutics8.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBBIOBridgeBio Pharma400195.86 million167.99 millionOptionableEVTCYEvotec4,200330.22 millionN/ANot OptionableNKTRNektar Therapeutics22033.79 million32.94 millionOptionableUTHRUnited Therapeutics1,40042.45 million38.80 millionOptionableUTHR, BBIO, NKTR, and EVTCY HeadlinesRecent News About These CompaniesInspire Investing LLC Has $5.88 Million Stock Holdings in United Therapeutics Corporation $UTHRJune 18 at 6:38 AM | marketbeat.comEvolve Private Wealth LLC Takes $6.83 Million Position in United Therapeutics Corporation $UTHRJune 18 at 6:02 AM | marketbeat.comElmind Capital LP Buys Shares of 11,000 United Therapeutics Corporation $UTHRJune 18 at 5:52 AM | marketbeat.comUnited Therapeutics Corporation $UTHR Holdings Increased by Eversept Partners LPJune 18 at 5:44 AM | marketbeat.comInsider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares of StockJune 17 at 5:45 AM | insidertrades.comInsider Selling: United Therapeutics (NASDAQ:UTHR) CFO Sells 10,000 Shares of StockJune 16 at 5:10 PM | marketbeat.comUnited Therapeutics Corporation $UTHR Shares Sold by L2 Asset Management LLCJune 16 at 8:17 AM | marketbeat.comUniversity of Texas Texas AM Investment Management Co. Makes New Investment in United Therapeutics Corporation $UTHRJune 16 at 7:14 AM | marketbeat.comUnited Therapeutics Corporation $UTHR Shares Bought by Sofinnova Investments Inc.June 16 at 6:46 AM | marketbeat.comUnited Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of StockJune 16 at 4:09 AM | americanbankingnews.comNicholas Investment Partners LP Increases Stake in United Therapeutics Corporation $UTHRJune 14, 2026 | marketbeat.comEventide Asset Management LLC Cuts Stock Holdings in United Therapeutics Corporation $UTHRJune 14, 2026 | marketbeat.comUnited Therapeutics Corporation $UTHR Position Lowered by Epoch Investment Partners Inc.June 14, 2026 | marketbeat.comUnited Therapeutics Corporation $UTHR Shares Sold by Aurora Investment CounselJune 14, 2026 | marketbeat.comInsider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $5,185,385.00 in StockJune 14, 2026 | americanbankingnews.comUnited Therapeutics (NASDAQ:UTHR) CFO Sells $5,492,900.00 in StockJune 12, 2026 | marketbeat.comMartine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) StockJune 12, 2026 | insidertrades.comFox Run Management L.L.C. Invests $1.28 Million in United Therapeutics Corporation $UTHRJune 10, 2026 | marketbeat.comUnited Therapeutics (NASDAQ:UTHR) CFO Sells $5,475,000.00 in StockJune 9, 2026 | marketbeat.comThese 3 Stocks Lowered Their Share Counts Drastically in Q1 (UTHR)...June 9, 2026 | marketbeat.comUnited Therapeutics Corporation $UTHR Shares Sold by Prudential PLCJune 9, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026The Smart Glasses Gold Rush Is Leaving Old-School Eyewear BehindBy Jeffrey Neal Johnson | May 24, 20263 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPOBy Ryan Hasson | May 20, 2026These 3 Stocks Lowered Their Share Counts Drastically in Q1By Leo Miller | June 9, 2026UTHR, BBIO, NKTR, and EVTCY Company DescriptionsBridgeBio Pharma NASDAQ:BBIO$66.68 -0.71 (-1.05%) As of 03:25 PM Eastern This is a fair market value price provided by Massive. Learn more.BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.Evotec OTCMKTS:EVTCY$2.61 -0.08 (-2.97%) As of 06/17/2026Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.Nektar Therapeutics NASDAQ:NKTR$59.77 -1.15 (-1.89%) As of 03:25 PM Eastern This is a fair market value price provided by Massive. Learn more.Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.United Therapeutics NASDAQ:UTHR$540.61 -10.86 (-1.97%) As of 03:25 PM Eastern This is a fair market value price provided by Massive. Learn more.United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge Jabil Just Gave Investors a Stronger Reason to Buy the Dip USA Rare Earth Just Moved Closer to Commercial Reality After an Initial Panic, Wall Street's Leaning Into Apple's New Siri AI CoreWeave Insider Sales Look Big, But Should Investors Worry? Can Trupanion Turn Pet Insurance Loyalty Into Real Earnings? Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
